Advertisement

Topics

Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions

03:15 EDT 2 Jun 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Novartis International AG / Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsi...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Novartis presents new data at EULAR and WCD further demonstrating its leadership in severe long-term inflammatory and skin conditions"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Wound management
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...